Abstract
The search for new highly-effective, fast-acting antidepressant drugs is extremely relevant. Brain derived neurotrophic factor (BDNF) and signaling through its tropomyosin-related tyrosine kinase B (TrkB) receptor, represents one of the most promising therapeutic targets for treating depression. BDNF is a key regulator of neuroplasticity in the hippocampus and the prefrontal cortex, the dysfunction of which is considered to be the main pathophysiological hallmark of this disorder. BDNF itself has no favorable drug-like properties due to poor pharmacokinetics and possible adverse effects. The design of small, proteolytically stable BDNF mimetics might provide a useful approach for the development of therapeutic agents. Two small molecule BDNF mimetics with antidepressant-like activity have been reported, 7,8-dihydroxyflavone and the dimeric dipeptide mimetic of BDNF loop 4, GSB-106. The article reflects on the current literature on the role of BDNF as a promising therapeutic target in the treatment of depression and on the current advances in the development of small molecules on the base of this neurotrophin as potential antidepressants.
Keywords: BDNF, depression, dimeric dipeptide mimetic, GSB-106, 7, 8-dihydroxyflavone, antidepressants.
[1]
Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64(2): 238-58.
[2]
Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A Key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol 2018; 38(3): 579-93.
[3]
Balaratnasingam S, Janca A. Brain Derived Neurotrophic Factor: A novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 2012; 134(1): 116-24.
[5]
Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 1997; 378(1): 135-57.
[6]
Gonzalez A, Moya-Alvarado G, Gonzalez-Billaut C, Bronfman FC. Cellular and molecular mechanisms regulating neuronal growth by brain-derived neurotrophic factor. Cytoskeleton (Hoboken) 2016; 73(10): 612-28.
[7]
Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14(1): 7-23.
[8]
Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96(6): 857-68.
[9]
Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD. Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol 1999; 146(5): 955-66.
[10]
Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17(6): 596-603.
[11]
Li N, Lee B, Liu R-J, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329(5994): 959-64.
[12]
Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 2010; 70(5): 304-22.
[13]
Bruel-Jungerman E, Veyrac A, Dufour F, Horwood J, Laroche S, Davis S. Inhibition of PI3K-Akt signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus. PLoS One 2009; 4(11)e7901
[14]
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286(5443): 1358-62.
[15]
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci 2015; 11(6): 1164-78.
[16]
Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361(1473): 1545-64.
[17]
Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: A major mediator of neuronal neurotrophin responses. Neuron 1997; 19(5): 1031-47.
[18]
Alder J, Thakker-Varia S, Bangasser DA, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 2003; 23(34): 10800-8.
[19]
Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 2010; 70(5): 304-22.
[20]
Chiaramello S, Dalmasso G, Bezin L, et al. BDNF/ TrkB interaction regulates migration of SVZ precursor cells via PI3-K and MAP-K signalling pathways. Eur J Neurosci 2007; 26(7): 1780-90.
[21]
Ortiz-López L, Vega-Rivera NM, Babu H, Ramírez-Rodríguez GB. Brain-derived neurotrophic factor induces cell survival and the migration of murine adult hippocampal precursor cells during differentiation in vitro. Neurotox Res 2017; 31(1): 122-35.
[22]
Ma Z, Zang T, Birnbaum SG, et al. TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response. Nat Commun 2017; 8(1): 1668.
[23]
Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005; 25(49): 11288-99.
[24]
Mercado NM, Collier TJ, Sortwell CE, Steece-Collier K. BDNF in the Aged Brain: Translational Implications for Parkinson’s Disease. Austin Neurol Neurosci 2017; 2(2): 1021.
[25]
Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 2007; 81(5-6): 294-330.
[26]
Henriques A, Pitzer C, Schneider A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci 2010; 4: 32.
[27]
Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 2010; 7(4): 231-5.
[28]
Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 2013; 4: 45.
[29]
Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7(4): 243-50.
[30]
Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neuropharmacology 2014; 76(Pt C): 737-46.
[31]
Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M. Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(4): 499-504.
[32]
Phillips C. Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection. Neural Plast 2017; 20177260130
[33]
Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57(9): 1068-72.
[34]
Bus BA, Molendijk ML, Tendolkar I, et al. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Mol Psychiatry 2015; 20(5): 602-8.
[35]
Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007; 101(1-3): 239-44.
[36]
McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34(1): 41-54.
[37]
Cobb JA, Simpson J, Mahajan GJ, et al. Hippocampal volume and total cell numbers in major depressive disorder. J Psychiatr Res 2013; 47(3): 299-306.
[38]
Boldrini M, Santiago AN, Hen R, et al. Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 2013; 38(6): 1068-77.
[39]
Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 2008; 11(8): 1047-61.
[40]
Castrén E. Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol 2004; 4(1): 58-64.
[41]
Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60(8): 804-15.
[42]
Björkholm C, Monteggia LM. BDNF - a key transducer of antidepressant effects. Neuropharmacology 2016; 102: 72-9.
[43]
Molendijk ML, Bus BA, Spinhoven P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16(11): 1088-95.
[44]
Allen AP, Naughton M, Dowling J, et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J Affect Disord 2015; 186: 306-11.
[45]
Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23(1): 349-57.
[46]
Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008; 63(7): 642-9.
[47]
Wainwright SR, Galea LAM. The neural plasticity theory of depression: Assessing the roles of adult neurogenesis and psancam within the hippocampus. Neural Plasticity 2013; 2013: 1-14.
[48]
Dwivedi Y. Involvement of brain-derived neurotrophic factor in late-life depression. Am J Geriatr Psychiatry 2013; 21(5): 433-49.
[49]
Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-α. Biol Psychiatry 2004; 56(11): 819-24.
[50]
Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13(6): 467-75.
[51]
Liu R-J, Aghajanian GK. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci USA 2008; 105(1): 359-64.
[52]
Magariños AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience 1995; 69(1): 83-8.
[53]
Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry 2012; 2(3): 49-57.
[54]
Sterner EY, Kalynchuk LE. Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: relevance to depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(5): 777-90.
[55]
Chen H, Lombès M, Le Menuet D. Glucocorticoid receptor represses brain-derived neurotrophic factor expression in neuron-like cells. Mol Brain 2017; 10(1): 12.
[56]
Suri D, Vaidya VA. Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience 2013; 239: 196-213.
[57]
Jiang C, Salton SR. The role of neurotrophins in major depressive disorder. Transl Neurosci 2013; 4(1): 46-58.
[58]
Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21(17): 6706-17.
[59]
Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 2005; 192(2): 348-56.
[60]
Danzer SC, Crooks KRC, Lo DC, McNamara JO. Increased expression of brain-derived neurotrophic factor induces formation of basal dendrites and axonal branching in dentate granule cells in hippocampal explant cultures. J Neurosci 2002; 22(22): 9754-63.
[61]
Hu B, Nikolakopoulou AM, Cohen-Cory S. BDNF stabilizes synapses and maintains the structural complexity of optic axons in vivo. Development 2005; 132(19): 4285-98.
[62]
Duman RS, Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci 2012; 367(1601): 2475-84.
[63]
Gottmann K, Mittmann T, Lessmann V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp Brain Res 2009; 199(3-4): 203-34.
[64]
Gärtner A, Polnau DG, Staiger V, et al. Hippocampal long-term potentiation is supported by presynaptic and postsynaptic tyrosine receptor kinase B-mediated phospholipase Cgamma signaling. J Neurosci 2006; 26(13): 3496-504.
[65]
Pozzo-Miller LD, Gottschalk W, Zhang L, et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J Neurosci 1999; 19(12): 4972-83.
[66]
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92(19): 8856-60.
[67]
Xu B, Gottschalk W, Chow A, et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 2000; 20(18): 6888-97.
[68]
Korte M, Griesbeck O, Gravel C, et al. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci USA 1996; 93(22): 12547-52.
[69]
Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22(8): 3251-61.
[70]
Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037(1-2): 204-8.
[71]
Hu Y, Russek SJ. BDNF and the diseased nervous system: A delicate balance between adaptive and pathological processes of gene regulation. J Neurochem 2008; 105(1): 1-17.
[72]
Ibáñez CF. Neurotrophic factors: from structure-function studies to designing effective therapeutics. Trends Biotechnol 1995; 13(6): 217-27.
[73]
O’Leary PD, Hughes RA. Structure-activity relationships of conformationally constrained peptide analogues of loop 2 of brain-derived neurotrophic factor. J Neurochem 1998; 70(4): 1712-21.
[74]
O’Leary PD, Hughes RA. Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 2003; 278(28): 25738-44.
[75]
Wong AW, Giuffrida L, Wood R, et al. TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination. Mol Cell Neurosci 2014; 63: 132-40.
[76]
Fletcher JM, Hughes RA. Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. J Pept Sci 2006; 12(8): 515-24.
[77]
Fletcher JM, Morton CJ, Zwar RA, Murray SS, O’Leary PD, Hughes RA. Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. J Biol Chem 2008; 283(48): 33375-83.
[78]
Xiao J, Hughes RA, Lim JY, et al. A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination. J Neurochem 2013; 125(3): 386-98.
[79]
Massa SM, Yang T, Xie Y, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010; 120(5): 1774-85.
[80]
Simmons DA, Belichenko NP, Yang T, et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington’s disease. J Neurosci 2013; 33(48): 18712-27.
[81]
Li W, Bellot-Saez A, Phillips ML, Yang T, Longo FM, Pozzo-Miller L. A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice. Dis Model Mech 2017; 10(7): 837-45.
[82]
Schmid DA, Yang T, Ogier M, et al. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci 2012; 32(5): 1803-10.
[83]
Yu G, Wang W. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol 2015; 8(6): 6526-32.
[84]
Han J, Pollak J, Yang T, et al. Delayed administration of a small molecule TrkB ligand promotes recovery after hypoxic- ischemic stroke. Stroke 2012; 43(7): 1918-24.
[85]
Cardenas-Aguayo M del C, Kazim SF, Grundke-Iqbal I, Iqbal K. Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PLoS One 2013; 8(1)e53596
[86]
Zhang MW, Zhang SF, Li ZH, Han F. 7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress. Neurosci Lett 2016; 635: 33-8.
[87]
Liu X, Chan CB, Jang SW, et al. A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J Med Chem 2010; 53(23): 8274-86.
[88]
Spencer JPE. Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance. Proc Nutr Soc 2008; 67(2): 238-52.
[89]
Vauzour D, Vafeiadou K, Rice-Evans C, Williams RJ, Spencer JP. Activation of pro-survival Akt and ERK1/2 signalling pathways underlie the anti-apoptotic effects of flavanones in cortical neurons. J Neurochem 2007; 103(4): 1355-67.
[90]
Maher P, Akaishi T, Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci USA 2006; 103(44): 16568-73.
[91]
Choi J-Y, Kang J-T, Park S-J, et al. Effect of 7,8-dihydroxyflavone as an antioxidant on in vitro maturation of oocytes and development of parthenogenetic embryos in pigs. J Reprod Dev 2013; 59(5): 450-6.
[92]
Jang S-W, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 2010; 107(6): 2687-92.
[93]
Liu X, Obianyo O, Chan CB, et al. Biochemical and biophysical investigation of the brain-derived neurotrophic factor mimetic 7,8-dihydroxyflavone in the binding and activation of the TrkB receptor. J Biol Chem 2014; 289(40): 27571-84.
[94]
García-Díaz Barriga G, Giralt A, Anglada-Huguet M, et al. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington’s disease mouse model through specific activation of the PLCγ1 pathway. Hum Mol Genet 2017; 26(16): 3144-60.
[95]
Luo D, Shi Y, Wang J, et al. 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents. Neurosci Lett 2016; 620: 43-9.
[96]
Zhang Z, Liu X, Schroeder JP, et al. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2014; 39(3): 638-50.
[97]
Chen C, Li X-H, Zhang S, Tu Y, Wang YM, Sun HT. 7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction. Rejuvenation Res 2014; 17(3): 249-54.
[98]
Makar TK, Nimmagadda VKC, Singh IS, et al. TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis. J Neuroimmunol 2016; 292: 9-20.
[99]
Wang B, Wu N, Liang F, et al. 7,8-dihydroxyflavone, a small-molecule tropomyosin-related kinase B (TrkB) agonist, attenuates cerebral ischemia and reperfusion injury in rats. J Mol Histol 2014; 45(2): 129-40.
[100]
Zhao S, Yu A, Wang X, Gao X, Chen J. Post-injury treatment of 7,8-dihydroxyflavone promotes neurogenesis in the hippocampus of the adult mouse. J Neurotrauma 2016; 33(22): 2055-64.
[101]
Stagni F, Giacomini A, Guidi S, et al. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS. Exp Neurol 2017; 298(Pt A): 79-96.
[102]
Johnson RA, Lam M, Punzo AM, et al. 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J Appl Physiol 2012; 112(5): 704-10.
[103]
Yang Y-J, Li Y-K, Wang W, et al. Small-molecule TrkB agonist 7,8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia. Pharmacol Biochem Behav 2014; 122: 30-6.
[104]
Liu C, Chan CB, Ye K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Neurosci Lett 2016; 635: 33-8.
[105]
Zhang JC, Yao W, Dong C, et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 2015; 232(23): 4325-35.
[106]
Gudasheva TA, Antipova TA, Seredenin SB. Novel low-molecular-weight mimetics of the nerve growth factor. Dokl Biochem Biophys 2010; 434(4): 262-5.
[107]
Gudasheva TA, Tarasiuk AV, Pomogaĭbo SV, et al. [Design and synthesis of dipeptide mimetics of brain-derived neurotrophic factor]. Bioorg Khim 2012; 38(3): 280-90.
[108]
Gudasheva TA, Tarasiuk AV, Sazonova NM, Povarnina PY, Antipova TA, Seredenin SB. A novel dimeric dipeptide mimetic of the BDNF selectively activates the MAPK-Erk signaling pathway. Dokl Biochem Biophys 2017; 476(1): 291-5.
[109]
Logvinov IO, Antipova TA, Gudasheva TA, Tarasiuk AV, Antipov PI, Seredenin SB. Neuroprotective effects of dipeptide analogue of brain-derived neurotrophic factor GSB-106 in in vitro experiments. Bull Exp Biol Med 2013; 155(3): 343-5.
[110]
Gudasheva TA, Logvinov IO, Antipova TA, Seredenin SB. Brain-derived neurotrophic factor loop 4 dipeptide mimetic GSB-106 activates TrkB, Erk, and Akt and promotes neuronal survival in vitro. Dokl Biochem Biophys 2013; 451(1): 212-4.
[111]
Seredenin SB, Voronina TA, Gudasheva TA, et al. Antidepressant effect of dimeric dipeptide GSB-106, an original low-molecular-weight mimetic of BDNF. Acta Naturae 2013; 5(4): 105-9.
[112]
Gudasheva TA, Povatrnina P, Tallerova AV, Seredenin SB. Antidepressant-like activity of dimeric dipeptide mimetics of different BDNF hairpin loops is determined by the activation pattern of TrkB receptor signaling pathways. Int J Pharm Sci & Scient Res 2018; 4(7): 74-9.
[113]
Gudasheva TA, Povarnina PY, Seredenin SB. Dipeptide Mimetic of the Brain-derived Neurotrophic Factor Prevents Impairments of Neurogenesis in Stressed Mice. Bull Exp Biol Med 2017; 162(4): 454-7.
[114]
Gudasheva TA, Povarnina PY, Antipova TA, Seredenin SB. Dipeptide Mimetic of the BDNF GSB-106 with Antidepressant-Like Activity Stimulates Synaptogenesis. Dokl Biochem Biophys 2018; 481(1): 225-7.
[115]
Povarnina PY, Garibova TL, Gudasheva TA, Seredenin SB. Antidepressant effect of an orally administered dipeptide mimetic of the brain-derived neurotrophic factor. Acta Naturae 2018; 10(3): 81-4.
[116]
Nomura S, Shimizu J, Kinjo M, Kametani H, Nakazawa T. A new behavioral test for antidepressant drugs. Eur J Pharmacol 1982; 83(3-4): 171-5.
[117]
Povarnina P, Tallerova AV, Mezhlumyan AG, et al. Dimeric dipeptide BDNF mimetic GSB-106 is active at acute oral administration in a model of social defeat stress-induced depression in mice. Eksp Klin Farmakol: (Russia) 2019.
[118]
Gudasheva TA, Konstantinopolsky MA, Tarasiuk AV, Seredenin SB. Dipeptide mimetic of BDNF loop 4 exhibits analgesic activity. Dokl Biochem Biophys 2019.
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
Article Metrics
27
6